'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.

[1]  J. Barretina,et al.  Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification , 2010, International journal of cancer.

[2]  S. de Jong,et al.  Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. West,et al.  Expression of insulin-like growth factor 2 in mesenchymal neoplasms , 2009, Modern Pathology.

[4]  S. Avnet,et al.  Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. , 2009, Cancer research.

[5]  S. de Jong,et al.  The insulin‐like growth factor system and sarcomas , 2009, The Journal of pathology.

[6]  S. de Jong,et al.  Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL , 2008, British Journal of Cancer.

[7]  J. Fletcher,et al.  Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors , 2008, Oncogene.

[8]  C. Braconi,et al.  Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  D. Flieder,et al.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.

[10]  Narasimhan P. Agaram,et al.  Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.

[11]  B. Rikhof,et al.  Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. , 2007, Endocrine-related cancer.

[12]  J. Fletcher,et al.  KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway , 2007, Oncogene.

[13]  D. Postma,et al.  Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells , 2007, Journal of biochemical and molecular toxicology.

[14]  J. Fletcher,et al.  KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance , 2007, Oncogene.

[15]  H. Boezen,et al.  The insulin-like growth factor 1 receptor in cancer: old focus, new future. , 2007, European journal of cancer.

[16]  M. Lewitt,et al.  IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor. , 2007, Molecular human reproduction.

[17]  A. D. Van den Abbeele,et al.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  K. Owzar,et al.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .

[19]  Patrick E Carroll,et al.  The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma , 2007, Oncogene.

[20]  A. Hartmann,et al.  Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.

[21]  T. Nakajima,et al.  High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.

[22]  J. Fletcher,et al.  Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. , 2006, Cancer research.

[23]  N. Socci,et al.  Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor , 2006, Proceedings of the National Academy of Sciences.

[24]  S. Lessnick,et al.  IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1 , 2006, Oncogene.

[25]  Yang Feng,et al.  Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function , 2006, Molecular Cancer Therapeutics.

[26]  E. D. de Vries,et al.  Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells , 2005, British Journal of Cancer.

[27]  P. Wesseling,et al.  Differential patterns of insulin‐like growth factor‐I and ‐II mRNA expression in medulloblastoma , 2004, Neuropathology and applied neurobiology.

[28]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Fletcher,et al.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) , 2004, Oncogene.

[30]  J. van Doorn,et al.  Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia. , 2002, Clinical chemistry.

[31]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[32]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[33]  M. Elmlinger,et al.  Secretion of Noncomplexed ‘Big’ (10–18 kD) Forms of Insulin-Like Growth Factor-II by 12 Soft Tissue Sarcoma Cell Lines , 2000, Hormone Research in Paediatrics.

[34]  A. Costantino,et al.  Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.

[35]  D. Steiner,et al.  Post-translational Processing of the Insulin-like Growth Factor-2 Precursor , 1998, The Journal of Biological Chemistry.

[36]  V. Han,et al.  The expression of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. , 1996, The Journal of clinical endocrinology and metabolism.

[37]  J. Toretsky,et al.  Involvement of IGF-II in human cancer. , 1996, The Journal of endocrinology.

[38]  C. Woodworth,et al.  Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. , 1996, Cancer research.

[39]  E. Kohn,et al.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[40]  W. Greenlee,et al.  Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells. , 1989, Biochemistry.

[41]  M. Heinrich,et al.  Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target , 2009, International journal of cancer.